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Abstract: Betulinic acid is a natural product with a range of biological effects, for example 
potent antitumor activity. This anticancer property is linked to its ability to induce 
apoptotic cell death in cancer cells by triggering the mitochondrial pathway of apoptosis. 
In contrast to the cytotoxicity of betulinic acid against a variety of cancer types, normal 
cells and tissue are relatively resistant to betulinic acid, pointing to a therapeutic window. 
Compounds that exert a direct action on mitochondria present promising experimental 
cancer therapeutics, since they may trigger cell death under circumstances in which 
standard chemotherapeutics fail. Thus, mitochondrion-targeted agents such as betulinic 
acid hold great promise as a novel therapeutic strategy in the treatment of human cancers. 
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Abbreviations:  AIF, apoptosis inducing factor; Apaf-1, Apoptotic protease activating 
factor-1; BA, betulinic acid; DIABLO, direct IAP Binding protein with Low PI; HtrA2, 
high temperature requirement protein A; IAPs, Inhibitor of Apoptosis Proteins; MOMP, 
mitochondrial outer membrane permeabilization; ROS, reactive oxygen species; PARP, 
Poly (ADP-ribose) Polymerase; Smac, second mitochondria-derived activator of caspase; 
TNF, tumor necrosis factor; TRAIL, tumor necrosis factor-related apoptosis-inducing 
ligand; zVAD.fmk, N-benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone. 
 
 
1. Introduction 
Natural products have been used for combating human diseases for thousands of years, since they 
exhibit a wide range of biological properties that can be exploited for medical application [1]. 
Naturally occurring substances play an increasing role in drug discovery and development. In fact, the Int. J. Mol. Sci. 2008, 9 
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majority of anticancer and antiinfectious agents are of natural origin. The antitumor activity of natural 
products has been linked their ability to trigger cell death pathways including apoptosis in cancer cells. 
Apoptosis or programmed cell death is the cell’s intrinsic death program that plays a pivotal role in 
maintaining tissue homeostasis and that is highly conserved among different species [2]. Since 
apoptosis is involved in the regulation of many physiological processes, defective apoptosis signaling 
may lead to various pathological conditions. A hallmark of human cancers is evasion of apoptosis [3]. 
For example, cancer cells have the tendency to disable the mitochondrial (intrinsic) pathway of 
apoptosis. Besides their vital function for cellular bioenergetics mitochondria play a key role in the 
regulation of the point-of-no-return during apoptosis. Betulinic acid is a natural product that exhibits 
potent antitumor activities by triggering the mitochondrial path to apoptosis [4]. Mitochondrion-
targeted agents such as betulinic acid may open new perspectives to overcome some forms of drug 
resistance [4]. 
2. Betulinic acid, a phytochemical with antitumor activity 
Betulinic acid (3β, hydroxy-lup-20(29)-en-28-oic acid) is a pentacyclic triterpenoid of plant origin 
that is widely distributed in the plant kingdom throughout the world (Figure 1) [5]. For example, 
considerable amounts of betulinic acid are available in the outer bark of a variety of tree species, e.g. 
white-barked birch trees. The reduced congener of betulinic acid, betulin (3β-lup-20(29)-en-3,28-diol), 
was one of the first natural products identified and isolated from plants in 1788 [6]. Betulinic acid 
exerts a number of biological activities. For example, betulinic acid has been shown to have antitumor 
properties. To this end, it is interesting to note that white birch bark (Betula alba) which contains 
betulinic acid, has been used by Native Americans as a folk remedy.  
 
Figure 1. Structure of betulinic acid. 
 
HO
COOH
 
 
3. Mechanisms of action of betulinic acid 
Numerous studies over the last years aimed at elucidating the molecular mechanisms of betulinic 
acid-mediated antitumor activity. One characteristic feature of betulinic acid’s cytotoxicity is its ability 
to trigger the mitochondrial pathway of apoptosis in cancer cells. Apoptosis is an intrinsic program of 
cell death that is present in every cell and regulated by defined signaling pathways (Figure 2). Int. J. Mol. Sci. 2008, 9 
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Figure 2. Apoptosis pathways. Apoptosis pathways can be initiated at the level of the 
mitochondria by the release of apoptogenic factors such as cytochrome c, Smac or AIF 
from the mitochondrial intermembrane space into the cytosol (mitochondrial or intrinsic 
pathway) [51]. Smac promotes apoptosis by neutralizing “Inhibitor of Apoptosis Proteins” 
(IAP)-mediated inhibition of caspase-3 and -9 [51]. Alternatively, apoptosis can be 
triggered by ligation of death receptors (DR) such as CD95 or TRAIL receptors by their 
cognate ligands, i.e. CD95 ligand or TRAIL (receptor or extrinsic pathway) [52]. Death 
receptor stimulation in turn leads to receptor trimerization, recruitment of adaptor 
molecules such as FADD and activation of the initiator caspase-8, which propagates the 
death signal to effector caspases such as caspase-3 [52-54]. The BH3 domain only protein 
Bid links the receptor to the mitochondrial pathway [15]: Bid is activated by caspase-8-
mediated cleavage and translocates to mitochondria to promote cytochrome c release. 
Apoptosis can be inhibited by at various levels, e.g. by FLIP, Bcl-2 or IAPs [15, 55, 56]. 
 
3.1. Activation of the mitochondrial pathway by anticancer therapeutics 
The intrinsic (mitochondrial) pathway of apoptosis is triggered upon treatment with 
chemotherapeutic agents or upon radiotherapy as the result of a DNA damage or cellular stress 
response [7]. A pivotal initial step in the activation of the mitochondrial pathway is the 
permeabilization of the outer mitochondrial membrane [7]. During this process, both the mitochondrial 
outer and inner membranes are permeabilized, which in turn results in the release of soluble proteins Int. J. Mol. Sci. 2008, 9 
 
1099
from the mitochondrial interspace into the cytosol, for example cytochrome c, Smac or AIF [7]. A long 
list of protein factors and second messengers have been identified that can positively or negatively 
regulate permeabilization of the outer mitochondrial membrane [8]. Thus, factors that can directly 
induce mitochondrial outer membrane permeabilization can act as effective cytotoxic agents. 
3.2. Induction of mitochondrial outer membrane permeabilization by betulinic acid 
Betulinic acid has been reported to induce apoptosis via direct mitochondrial perturbations. When 
added to isolated mitochondria in cell-free systems, betulinic acid induced loss of mitochondrial 
membrane potential in a manner that was not affected by the caspase inhibitor zVAD.fmk and yet was 
inhibited by bongkrekic acid, an inhibitor of the permeability transition pore complex [9]. Also in 
intact cells, betulinic acid was shown to trigger cytochrome c in a caspase-independent and 
permeability transition pore-dependent manner [10]. In a cell-free system comprising mitochondria, 
cytosols, and purified nuclei, mitochondria undergoing betulinic acid-induced permeability transition 
mediated cytosolic caspase activation and nuclear fragmentation via the release of soluble factors, such 
as cytochrome c or AIF [9]. Antiapoptotic Bcl-2 family proteins such as Bcl-2 and Bcl-XL inhibited all 
mitochondrial and cellular manifestations of apoptosis induced by betulinic acid, as did bongkrekic 
acid [9], indicating that mitochondrial permeability transition is required for these events. Perturbance 
of mitochondrial function constitutes a central coordinating event in betulinic acid-induced apoptosis 
leading to caspase activation and apoptotic DNA fragmentation. Mitochondria from cells, which were 
treated with betulinic acid, induced cleavage of both caspase-8 and caspase-3 in cytosolic extracts. 
Cytochrome c, released from mitochondria undergoing betulinic acid-mediated permeability transition, 
activated caspase-3 but not caspase-8 in a cell-free system. Cleavage of caspase-3 and -8 was preceded 
by disturbance of mitochondrial membrane potential and by generation of reactive oxygen species. In 
addition, activation of caspases was restricted to cells that already had lost their mitochondrial 
membrane potential further suggesting that mitochondrial alterations were involved in betulinic acid-
induced activation of caspases. Overexpression of Bcl-2 and Bcl- XL conferred resistance to betulinic 
acid at the level of mitochondrial dysfunction, protease activation, and nuclear fragmentation 
indicating that these events occurred downstream of the Bcl-2- or Bcl-XL-controlled checkpoint of 
apoptosis. These findings suggest that caspase-8 is activated downstream of mitochondria during 
betulinic acid-induced apoptosis. Activation of the caspase cascade was required for betulinic acid-
triggered apoptosis, as broad-spectrum peptide inhibitors of caspases completely abrogated betulinic 
acid-triggered apoptosis. Interestingly, neuroblastoma cells resistant to doxorubicin-mediated 
apoptosis were still responsive to treatment with betulinic acid [11]. This suggests that betulinic acid 
may overcome some forms of drug resistance.  
Generation of reactive oxygen species (ROS) upon treatment with betulinic acid has been reported 
to be involved in initiating mitochondrial membrane permeabilization. To this end, ROS generation 
was detected in cancer cell lines of different origin that were treated with betulinic acid [12-14]. 
Incubation with antioxidants prior to adminstration of betulinic acid rescued cells from undergoing 
apoptosis suggesting that ROS production was involved in mediating cell death. Also, ROS generation 
was linked to activation of pro-apoptotic p38 and SAP/JNK kinases with no change in the 
phosphorylation of ERK indicating that ROS act upstream of the MAPKs in the signaling pathway of 
betulinic acid [13]. Int. J. Mol. Sci. 2008, 9 
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3.3. Regulation of betulinic acid-induced apoptosis by Bcl-2 family proteins  
Proteins of the Bcl-2 family are among the many signal transduction proteins that can act on 
mitochondria to regulate outer membrane permabilization. Bcl-2 family proteins comprise both anti-
apoptotic members, e.g. Bcl-2, Bcl-XL, Mcl-1, as well as pro-apoptotic molecules such as Bax, Bak, 
Bad and BH3 domain only molecules [15]. Imbalances in the ratio of anti-apoptotic versus pro-
apoptotic Bcl-2 proteins may tip the balance in favor of tumor cell survival instead of cell death [15]. 
Betulinic acid has been reported to modulate expression levels of different Bcl-2 family proteins. 
For example, treatment with betulinic acid resulted in upregulation of the pro-apoptotic Bcl-2 family 
protein Bax in neuroblastoma, glioblastoma and melanoma cells, whereas Bcl-XS was found at 
elevated levels in betulinic acid-treated neuroblastoma cells [12, 14, 16]. Expression levels of pro-
apoptotic proteins Bak and Bad were not altered in response to betulinic acid in melanoma cells [16, 
17]. While expression levels of anti-apoptotic Bcl-2 remained unchanged upon incubation with 
betulinic acid in neuroblastoma and squamous cell carcinoma cells, an increase in Bcl-2 protein levels 
was reported in glioblastoma cells [12, 14, 18]. Also, betulinic acid triggered upregulation of Mcl-1, 
another anti-apoptotic Bcl-2 family protein, in melanoma cells, whereas no changes in Mcl-1 levels 
were detected in squamous cell carcinoma cells [16-18]. As fas as Bcl-XL is concerned, no alterations 
in expression levels were reported upon exposure to betulinic acid in neuroblastoma, glioblastoma or 
melanoma cells [12, 14, 17]. These findings suggest that betulinic acid regulates Bcl-2 family proteins 
in a context-dependant manner. 
Moreover, betulinic acid has been reported to induce apoptosis in a p53- and CD95-independent 
manner. To this end, apoptosis upon treatment with betulinic acid was not associated with 
accumulation of wild-type p53 protein [12, 14, 16, 19-21]. Also, betulinic acid similarly induced 
apoptosis in p53 mutant and p53 wild-type cell lines and was also active in p53 deficient melanoma 
cells [16, 22]. Moreover, betulinic acid triggered apoptosis independent of CD95-ligand/receptor 
interaction [12, 14, 23].  
3.4. Modulation of NF-κB activity by betulinic acid  
Betulinic acid has also been reported to modulate activity of the transcription factor nuclear factor-
κB (NF-κB), a key regulator of stress-induced transcriptional activation. Betulinic acid was identified 
as a potent activator of NF-κB in a number of cancer cell lines [24]. Betulinic acid-induced NF-κB 
activation involved increased IKK activity, phosphorylation of IκBα at serine 32/36 followed by 
degradation of IκBα and nuclear translocation of the NF-κB subunit p65. Reporter assays confirmed 
that NF-κB that was activated by betulinic acid is transcriptionally active. Interestingly, inhibition of 
betulinic acid-induced NF-κB activation by different chemical inhibitors (proteasome inhibitor, 
antioxidant, IKK inhibitor) also impaired betulinic acid-induced apoptosis. Importantly, specific NF-
κB inhibition by transient or stable expression of IκBα super-repressor inhibited betulinic acid-
induced apoptosis in some neuroblastoma cells, while transient expression of IκBα super-repressor 
had no influence on betulinic acid-induced apoptosis in other cell lines. These findings indicate that 
activation of NF-κB by betulinic acid promotes betulinic acid-induced apoptosis in a cell type-specific 
manner. By comparison, betulinic acid was shown to interfere with NF-κB activation and NF-κB-
regulated gene expression triggered by carcinogens and inflammatory stimuli [25]. These findings may Int. J. Mol. Sci. 2008, 9 
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provide a molecular basis for the ability of betulinic acid to suppress inflammation and modulate the 
immune response. Together, these findings point to a context-dependant function of NF-κB in the 
regulation of betulinic acid-mediated apoptosis.  
4. Additional anticancer effects of betulinic acid 
Betulinic acid has also been reported to inhibit aminopeptidase N, an enzyme that is involved in the 
regulation of angiogenesis and overexpressed in several cancers [26-28]. In addition, betulinic acid 
was reported to exert antiangiogenic effects by inhibiting growth factor-induced in vitro angiogenesis 
in endothelial cells, possibly by affecting mitochondrial functions [26]. Further, the antiangiogenic 
activity of betulinic acid was attributed to activation of selective proteasome-dependent degradation of 
the transcription factors specificity protein 1 (Sp1), Sp3, and Sp4, which regulate vascular endothelial 
growth (VEGF) expression [29]. Compared to betulinic acid, 20,29-dihydro-betulinic acid derivatives 
were claimed to posses better anti-angiogenic properties as betulinic acid [30]. Also, betulinic acid was 
shown to inhibit the catalytic activity of topoisomerase I [31]. Furthermore, betulinic acid exerts 
context-dependant effects on the cell cycle. While betulinic acid was found to reduce expression of 
p21 protein in melanoma cells, an increase of p21 protein was observed upon treatment with betulinic 
acid in glioblastoma cells [12, 32]. Alterations in cell cycle progression in response to betulinic acid 
were also highly dependant on individual cell lines [32]. Whether betulinic acid-mediated cell cycle 
changes are linked to its antitumor activity remains to be addressed in future studies. 
5. Anticancer activity of betulinic acid 
The antitumor cytotoxicity of betulinic acid has been extensively studied in a panel of cancer cell 
lines, primary tumor samples and xenograft mouse models (Table 1). While initial reports suggested 
that betulinic acid is selectively cytotoxic against melanoma cell lines [33], anticancer activity was 
subsequently also reported against other types of human cancers including neuroblastoma, 
glioblastoma, medulloblastoma, Ewing tumor, leukemia as well as several carcinoma, i.e. head and 
neck, colon, breast, hepatocellular, lung, prostate, renal cell, ovarian or cervix carcinoma [12, 14, 18, 
22, 23, 34-39]. In addition to tumor cell lines, Betulinic acid was also cytotoxic against primary cancer 
cells isolated from tumor specimens obtained from neuroblastoma, glioblastoma and leukemia [14, 23, 
38, 39]. Also, betulinic acid was cytotoxic in different models of drug resistance, for example primary 
pediatric acute leukemia samples that were refractory to standard chemotherapeutic agents [14, 23]. 
Thus, betulinic acid may overcome certain forms of drug resistance. Further, there is evidence that 
betulinic acid is preferentially cytotoxicity against metastatic over non-metastatic melanoma cell lines 
[32]. Moreover, betulinic acid cooperated with different cytotoxic stimuli to suppress tumor growth, 
including ionizing radiation [16], chemotherapeutic drugs [40] [41] or the death recpetor ligand 
TRAIL [42]. This suggests that betulinic acid may be used as sensitizer in combination regimens to 
enhance the efficacy of anticancer therapy. By comparison, normal cells of different origin have been 
reported to be much more resistant to betulinic acid than cancer cells pointing to some tumor 
selectivity [16, 22, 38, 39]. Int. J. Mol. Sci. 2008, 9 
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Table 1. In vitro cytotoxic effect of betulinic acid on human cancer cell lines. 
Cancer type  ED50 (μg/ml)  References 
melanoma 1.1-4.8    [33] 
neuroblastoma 2-10    [14] 
medulloblastoma 3-15    [39] 
glioblastoma 5-16    [39] 
head & neck cancer  8   [18] 
ovarian carcinoma  1.8-4.5   [22] 
cervix carcinoma  1.8   [22] 
lung carcinoma  1.5-4.2   [22] 
leukemia 2-15    [23] 
 
Besides its potent antitumor activity in vitro, betulinic acid also suppressed tumor growth in several 
animal models of human cancer. In a xenograft mouse model of ovarian cancer administration of 
betulinic acid significantly increased the survival time [22]. Also, betulinic acid suppressed tumor 
growth in a melanoma xenograft model [33]. Also in vivo, betulinic acid cooperated with 
chemotherapeutic agents such as vincristin to reduce lung metastasis in a metastatic melanoma model 
[41]. Of note, no systemic toxicities or weights loss were observed in betulinic acid-treated mice even 
at high systemic doses of betulinic acid [22, 33]. Pharmacokinetic studies in mice bearing melanoma 
xenografts demonstrated that betulinic acid was well absorbed and distributed with highest 
concentrations found within the tumor [43, 44]. Phase I/II studies of 3-o-(3',3'-dimethylsuccinyl) 
betulinic acid (bevirimat) in patients with human immunodeficiency virus (HIV) infection 
demonstrated that single oral doses of bevirimat were well tolerated and that plasma concentrations 
ranged from 8 to 58 μg/ml [45, 46]. This indicates that plasma levels of betulinic acid could be 
achieved after oral administration in humans that correspond to concentrations, which were found to 
exert antitumor activity in vitro. 
Furthermore, betulinic acid was reported to harbor anticarcinogenic properties that could be 
exploited in cancer prevention settings. To this end, betulinic acid was shown already more than a 
decade ago to inhibit tumor formation in mouse skin two-stage carcinogenesis [47]. Betulinic acid is 
currently under evaluation as a topical agent in a phase I/II clinical trial for the treatment of dysplastic 
nevi with the potential to transform into melanoma.  
In addition to betulinic acid, a variety of betulinic acid derivatives were developed with the aim to 
increase the anticancer potency and to improve the pharmacokinetic properties. For example, replacing 
the cyano group with a methoxycarbonyl was reported to markedly enhance the apoptosis-inducing 
activities of betulinic acid [48]. In addition, these new BA analogues showed higher plasma and tissue 
levels compared to betulinic acid [48]. Further, C-3 modified Betulinic acid derivatives proved to have 
better in vivo anti-tumor efficacy as compared to betulinic acid in vivo against human colon cancer and 
also displayed favorable pharmacokinetic properties [49]. Moreover, 17-carboxylic acid modified 23-
hydroxy betulinic acid ester derivatives demonstrated for cytotoxic activity on five cancer cell lines in Int. J. Mol. Sci. 2008, 9 
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vitro: all tested compounds showed higher cytotoxic activity as compared to 23-hydroxy betulinic acid 
and betulinic acid in vitro and also in vivo [50]. 
6. Conclusions 
The natural compound betulinic acid shows potent anticancer activity through activation of the 
mitochondrial pathway of apoptosis in cancer cells. Betulinic acid may also be used in combination 
protocols to enhance its antitumor activity, for example with chemo- or radiotherapy or with the death 
receptor ligand TRAIL. Because of its relative selective cytotoxicity against malignant compared to 
normal cells, betulinic acid is a promising new experimental anticancer agents for the treatment of 
human cancers. 
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